This chapter describes an in vitro coculture experiment to study functionality and antitumor efficacy of engineered measles vaccine strain virus encoding natural killer cell engagers. In a flow cytometry-based analysis, target cell death of noninfected bystander cancer cells and effector functions of ...
Previous studies have engineered ADVs to express proteins such as relaxin, T-cell engagers, and costimulatory molecules [21,22,23]. Thus, gene modification of ADVs to construct novel therapeutic oncolytic ADVs expressing various proteins is a promising and feasible approach for overcoming the ...
2.2.1.1. Activating T cells using T-cell engager bsAb Most bsAbs undergoing clinical trials comprise CD3-binding, bispecific T cell engagers (TCEs). These TCEs specifically bind to CD3, a constituent of the T cell receptor/CD3 protein complex expressed on the T cell surface, as well as to...
Tri-functional T-cell engagers target immune checkpoint inhibitors PD-1 and TIGIT to enhance CD8 effector T-cell functions in chronically SHIV-infected rhesus macaquesCheckpoint inhibitors, such as PD-1 and TIGIT, are crucial dysregulators of CD8 T cell function during chronic HIV/SIV infections. ...
Introduction: Immunotherapy for T-cell leukemias/lymphomas (TCLL) is not clinically available unlike B cell malignancies. In particular, bispecific T-cell engagers (BTCE) have been poorly developed because malignant cells express surface CD3, which makes anti-CD3 antibodies unavailable. Recently, ...
Today, T cell-engagers are generated as a wide variety of molecular architectures, typically IgG-type. However, nearly without exception, these bispecifics are generated by genetic fusion of a cancer-binding and an anti-CD3 antibody, which inevitably requires genetic reengineering of an existing ...
With the rise of powerful new uses of antibody therapy such as bispecific T-cell engagers, antibody-drug conjugates, and checkpoint inhibitors, it is increasingly important to optimize the Fc region as well as the antibody binding site in order to achieve the best combination of saf...
Although great efficacy has been observed for T-cell engagers, balance of safety-efficacy remains a major concern. Bispecific antibody (BsAb) with lower CD3-binding arm could have a huge potential to minimize unspecific T-cell activation while maintaining better-efficacy. Here, we designed Claudin ...